Current management of sepsis in critically ill adult patients

被引：0

作者：

Vincent, Jean-Louis ^{[1
]}

Serrano, Elena Carrasco ^{[1
]}

Dimoula, Aikaterina ^{[1
]}

机构：

[1] Univ Libre Bruxelles, Dept Intens Care, Erasme Hosp, Brussels, Belgium

来源：

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY | 2011年 / 9卷 / 07期

关键词：

antibiotics; corticosteroids; drotrecogin alfa (activated); fluid challenge; infection; vasopressors; RENAL-REPLACEMENT THERAPY; INTENSIVE INSULIN THERAPY; ACUTE KIDNEY INJURY; SEPTIC SHOCK; VASOPRESSIN INFUSION; CLINICAL-TRIALS; CARE UNITS; PROTEIN-C; BLOOD; NOREPINEPHRINE;

D O I：

10.1586/ERI.11.65

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Severe sepsis is a common occurrence in critically ill patients and a major cause of morbidity and mortality in this population. Management relies on the early identification and treatment of the underlying causative infection, adequate and rapid hemodynamic resuscitation, support of associated organ failure and modulation of the immune response with drotrecogin alfa (activated) when it is not contraindicated, and corticosteroids in severe septic shock. We will review current approaches to each of these categories.

引用

页码：847 / 856

页数：10

共 77 条

[1] Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death [J].

Abraham, E ;

Laterre, P ;

Garg, R ;

Levy, H ;

Talwar, D ;

Trzaskoma, BL ;

Francois, B ;

Guy, JS ;

Bruckmann, M ;

Rea-Neto, A ;

Rossaint, R ;

Perrotin, D ;

Sablotzki, A ;

Arkins, N ;

Utterback, BG ;

Macias, WL .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (13) :1332-1341

[2]

Andrikos Emilios, 2009, Blood Purif, V28, P239, DOI 10.1159/000231986

[3] Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis [J].

Angus, DC ;

Linde-Zwirble, WT ;

Clermont, G ;

Ball, DE ;

Basson, BR ;

Ely, EW ;

Laterre, PF ;

Vincent, JL ;

Bernard, G ;

van Hout, B .

CRITICAL CARE MEDICINE, 2003, 31 (01) :1-11

[4] Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock [J].

Annane, D ;

Sébille, V ;

Charpentier, C ;

Bollaert, PE ;

François, B ;

Korach, JM ;

Capellier, G ;

Cohen, Y ;

Azoulay, E ;

Troché, G ;

Chaumet-Riffaut, P ;

Bellissant, E .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (07) :862-871

[5]

*ANZICS STUD GROUP, 2007, CRIT CARE RESUSC, V9, P8

[6] Vasopressin: Mechanisms of action on the vasculature in health and in septic shock [J].

Barrett, Lucinda K. ;

Singer, Mervyn ;

Clapp, Lucie H. .

CRITICAL CARE MEDICINE, 2007, 35 (01) :33-40

[7]

Bellomo R, 2009, NEW ENGL J MED, V361, P1627, DOI 10.1056/NEJMoa0902413

[8] Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis [J].

Bernard, GR ;

Macias, WL ;

Joyce, DE ;

Williams, MD ;

Bailey, J ;

Vincent, JL .

CRITICAL CARE, 2003, 7 (02) :155-163

[9] Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].

Bernard, GR ;

Vincent, JL ;

Laterre, P ;

LaRosa, SP ;

Dhainaut, JF ;

Lopez-Rodriguez, A ;

Steingrub, JS ;

Garber, GE ;

Helterbrand, JD ;

Ely, EW ;

Fisher, CJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709

[10] A multicenter trial to compare blood culture with polymerase chain reaction in severe human sepsis [J].

Bloos, Frank ;

Hinder, Frank ;

Becker, Karsten ;

Sachse, Svea ;

Dessap, Armand Mekontso ;

Straube, Eberhard ;

Cattoir, Vincent ;

Brun-Buisson, Christian ;

Reinhart, Konrad ;

Peters, Georg ;

Bauer, Michael .

INTENSIVE CARE MEDICINE, 2010, 36 (02) :241-247

← 1 2 3 4 5 6 7 8 →